Medical Information

Inquiry handling, response quality, topic trends and escalations (PRD §16). Source: MI inquiry platform (INT-05), hourly.

Inquiry volume YTD

840

Last 30 days vs prior 30

111(+11 vs 100)

SLA compliance

78.6%

Target 92%-13.4% vs target+0.8

Median response time

45h

Target 48h-3h vs target-3

Open / overdue

13 / 3

Escalation rate

6.5%

Standard-response reuse

62%

Target 65%-3% vs target+1

Safety-related inquiries

Repeat inquiry rate (approx.)

75%

Definitions

SLA compliance and median response are computed over responded inquiries. Repeat rate is the share of topic + country pairs with two inquiries ≤ 30 days apart — an approximation.

Monthly volume by product

Inquiries received, Jan–Sep 2026

Jan 93 · Feb 85 · Mar 85 · Apr 113 · May 91 · Jun 106 · Jul 107 · Aug 98 · Sep 62

SLA compliance per month

Responded inquiries answered within the urgency-based SLA · target 92%

Jan 73.1% · Feb 76.5% · Mar 72.9% · Apr 82.3% · May 85.7% · Jun 81.1% · Jul 74.8% · Aug 79.6% · Sep 81.6%

Inquiries (840)

ID	Received	Channel	Requestor	Country	Product	Topic	Category	Urgency	Response	Owner	Status	SLA	Due	Quality review
MI-2026-0649	15 Sept 2026, 13:22	MSL	Patient	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Received	Open	in 5 days	Pending
MI-2026-0812	14 Sept 2026, 08:12	MSL	HCP	DE	Nephrada	Recurrent infections on extended treatment	Safety	Critical	Custom	Fatima Al-Sayed	Escalated	Overdue	today	Pending
MI-2026-0282	13 Sept 2026, 17:22	Web portal	Internal	GB	Nephrada	Vaccination guidance	Safety	Routine	Standard	Dr. Anna Becker	Triage	Open	in 3 days	Pending
MI-2026-0526	13 Sept 2026, 16:10	Email	Internal	FR	Vantrexa	Storage after dilution	Storage	Routine	Standard	Rachel Adeyemi	In progress	Open	in 3 days	Pending
MI-2026-0301	13 Sept 2026, 13:21	Web portal	Patient	DE	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Fatima Al-Sayed	In progress	Open	in 3 days	Pending
MI-2026-0493	13 Sept 2026, 07:50	Phone	Payer	GB	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Triage	Open	in 3 days	Pending
MI-2026-0438	12 Sept 2026, 14:50	Email	Payer	DE	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Fatima Al-Sayed	In progress	Open	in 2 days	Pending
MI-2026-0088	12 Sept 2026, 09:35	Phone	HCP	AU	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Routine	Custom	Luis Ortega	Medical review	Open	in 2 days	Pending
MI-2026-0555	12 Sept 2026, 08:18	Phone	HCP	DE	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Fatima Al-Sayed	In progress	Open	in 2 days	Pending
MI-2026-0755	11 Sept 2026, 15:59	Web portal	HCP	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	In progress	Open	tomorrow	Pending
MI-2026-0726	11 Sept 2026, 10:35	Web portal	HCP	GB	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Standard	Fatima Al-Sayed	Triage	Overdue	2 days ago	Pending
MI-2026-0160	10 Sept 2026, 16:54	Phone	Patient	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	In progress	Open	today	Pending
MI-2026-0431	10 Sept 2026, 07:58	MSL	Pharmacist	IT	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Fatima Al-Sayed	Received	Overdue	today	Pending
MI-2026-0634	15 Sept 2026, 17:28	Web portal	HCP	DE	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Sent	Breached	in 5 days	Passed
MI-2026-0619	14 Sept 2026, 15:59	Web portal	HCP	DE	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Urgent	Standard	Luis Ortega	Sent	Breached	tomorrow	Not required
MI-2026-0647	14 Sept 2026, 12:32	Email	Payer	GB	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	in 4 days	Passed
MI-2026-0107	14 Sept 2026, 12:23	Email	Pharmacist	IT	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	in 4 days	Not required
MI-2026-0489	13 Sept 2026, 17:08	Phone	HCP	FR	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Sent	Within SLA	in 3 days	Passed
MI-2026-0374	13 Sept 2026, 15:41	Email	Pharmacist	DE	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	in 3 days	Not required
MI-2026-0233	12 Sept 2026, 08:37	MSL	Payer	DE	Vantrexa	Storage after dilution	Storage	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	in 2 days	Not required
MI-2026-0408	11 Sept 2026, 10:12	Phone	Patient	JP	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Rachel Adeyemi	Closed	Breached	tomorrow	Passed
MI-2026-0714	10 Sept 2026, 16:15	Web portal	Internal	FR	Vantrexa	Dose delay for grade 2 irAE	Dosing	Urgent	Standard	Fatima Al-Sayed	Sent	Within SLA	3 days ago	Not required
MI-2026-0296	10 Sept 2026, 13:45	Congress booth	HCP	US	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Luis Ortega	Sent	Within SLA	today	Not required
MI-2026-0178	10 Sept 2026, 08:55	Email	HCP	US	Vantrexa	Storage after dilution	Storage	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	today	Not required
MI-2026-0069	09 Sept 2026, 13:10	Phone	Payer	JP	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Breached	yesterday	Passed
MI-2026-0672	09 Sept 2026, 13:03	MSL	Payer	CA	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	yesterday	Not required
MI-2026-0433	09 Sept 2026, 12:14	Congress booth	Internal	DE	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	yesterday	Passed
MI-2026-0656	09 Sept 2026, 07:50	MSL	HCP	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Closed	Breached	yesterday	Passed
MI-2026-0195	08 Sept 2026, 18:18	Email	HCP	DE	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	2 days ago	Not required
MI-2026-0763	08 Sept 2026, 11:32	Congress booth	HCP	FR	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Rachel Adeyemi	Closed	Within SLA	2 days ago	Passed
MI-2026-0588	08 Sept 2026, 07:29	Web portal	Patient	DE	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	2 days ago	Not required
MI-2026-0772	07 Sept 2026, 16:08	Phone	HCP	US	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Standard	Fatima Al-Sayed	Closed	Breached	6 days ago	Not required
MI-2026-0321	07 Sept 2026, 15:42	Phone	HCP	GB	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	3 days ago	Not required
MI-2026-0388	07 Sept 2026, 12:35	MSL	Internal	DE	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	3 days ago	Not required
MI-2026-0788	07 Sept 2026, 10:40	Email	HCP	ES	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	3 days ago	Passed
MI-2026-0511	07 Sept 2026, 10:03	Web portal	Internal	DE	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	3 days ago	Not required
MI-2026-0358	07 Sept 2026, 09:32	Web portal	Internal	GB	Vantrexa	Dose delay for grade 2 irAE	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	3 days ago	Not required
MI-2026-0628	07 Sept 2026, 09:20	Email	Pharmacist	DE	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	3 days ago	Not required
MI-2026-0616	07 Sept 2026, 08:56	Email	HCP	JP	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Breached	3 days ago	Passed
MI-2026-0799	06 Sept 2026, 16:39	Web portal	Patient	DE	Lumeva	Missed-dose guidance	Dosing	Urgent	Standard	Fatima Al-Sayed	Closed	Within SLA	7 days ago	Not required
MI-2026-0054	06 Sept 2026, 15:38	Email	Patient	DE	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Urgent	Custom	Fatima Al-Sayed	Closed	Breached	7 days ago	Passed
MI-2026-0538	06 Sept 2026, 15:12	Web portal	Payer	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Closed	Within SLA	4 days ago	Passed
MI-2026-0010	06 Sept 2026, 12:32	Web portal	HCP	GB	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Dr. Anna Becker	Sent	Within SLA	4 days ago	Not required
MI-2026-0032	06 Sept 2026, 11:04	Web portal	Pharmacist	US	Lumeva	Use in pregnancy	Safety	Routine	Standard	Luis Ortega	Closed	Within SLA	4 days ago	Not required
MI-2026-0666	06 Sept 2026, 07:26	Web portal	Payer	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	4 days ago	Passed
MI-2026-0507	05 Sept 2026, 18:18	Congress booth	HCP	US	Vantrexa	Reimbursement status by country	Access	Urgent	Standard	Fatima Al-Sayed	Closed	Within SLA	8 days ago	Not required
MI-2026-0353	05 Sept 2026, 16:16	Email	Internal	GB	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	5 days ago	Not required
MI-2026-0157	05 Sept 2026, 14:23	MSL	HCP	US	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	5 days ago	Not required
MI-2026-0266	05 Sept 2026, 08:17	MSL	HCP	IT	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	5 days ago	Not required
MI-2026-0087	04 Sept 2026, 18:23	Web portal	Pharmacist	DE	Nephrada	Mechanism versus budesonide formulations	Efficacy	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	6 days ago	Not required
MI-2026-0614	04 Sept 2026, 15:15	Email	HCP	US	Nephrada	Vaccination guidance	Safety	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	6 days ago	Not required
MI-2026-0190	04 Sept 2026, 12:32	Web portal	HCP	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Closed	Within SLA	6 days ago	Passed
MI-2026-0386	04 Sept 2026, 11:27	Congress booth	Patient	IT	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	6 days ago	Not required
MI-2026-0224	04 Sept 2026, 09:31	Email	Pharmacist	US	Vantrexa	Dose delay for grade 2 irAE	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	6 days ago	Not required
MI-2026-0473	04 Sept 2026, 08:25	Email	HCP	US	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	6 days ago	Not required
MI-2026-0751	03 Sept 2026, 16:42	Phone	HCP	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	7 days ago	Passed
MI-2026-0014	03 Sept 2026, 13:44	Email	HCP	GB	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	7 days ago	Not required
MI-2026-0062	03 Sept 2026, 13:03	Email	Pharmacist	US	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	7 days ago	Not required
MI-2026-0248	03 Sept 2026, 11:29	Web portal	HCP	JP	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	7 days ago	Passed
MI-2026-0222	02 Sept 2026, 10:45	Congress booth	Pharmacist	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	8 days ago	Passed
MI-2026-0096	02 Sept 2026, 08:29	MSL	Payer	DE	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	8 days ago	Not required
MI-2026-0795	01 Sept 2026, 14:31	Phone	Patient	FR	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Rachel Adeyemi	Closed	Breached	9 days ago	Passed
MI-2026-0300	31 Aug 2026, 13:53	Web portal	Internal	CA	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	10 days ago	Not required
MI-2026-0393	31 Aug 2026, 11:44	Phone	Internal	US	Lumeva	Use in pregnancy	Safety	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	10 days ago	Not required
MI-2026-0739	31 Aug 2026, 08:55	Email	Payer	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Closed	Within SLA	10 days ago	Passed
MI-2026-0836	31 Aug 2026, 08:08	Congress booth	HCP	GB	Nephrada	Vaccination guidance	Safety	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	10 days ago	Not required
MI-2026-0524	31 Aug 2026, 07:59	Web portal	HCP	GB	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	10 days ago	Not required
MI-2026-0145	30 Aug 2026, 18:13	Email	HCP	US	Aurelin	Phase IIb results availability	Efficacy	Urgent	Standard	Fatima Al-Sayed	Sent	Breached	14 days ago	Not required
MI-2026-0270	30 Aug 2026, 17:04	Congress booth	Payer	CA	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	11 days ago	Not required
MI-2026-0729	30 Aug 2026, 16:08	Web portal	Internal	JP	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	11 days ago	Not required
MI-2026-0637	30 Aug 2026, 10:02	Phone	HCP	GB	Nephrada	Vaccination guidance	Safety	Urgent	Standard	Dr. Anna Becker	Closed	Within SLA	14 days ago	Not required
MI-2026-0285	30 Aug 2026, 08:31	Email	Pharmacist	DE	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	11 days ago	Not required
MI-2026-0402	29 Aug 2026, 15:36	Web portal	HCP	FR	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	12 days ago	Not required
MI-2026-0340	28 Aug 2026, 18:19	Web portal	Internal	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Breached	13 days ago	Passed
MI-2026-0764	28 Aug 2026, 15:47	MSL	HCP	IT	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	13 days ago	Passed
MI-2026-0166	28 Aug 2026, 15:44	Congress booth	HCP	US	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	13 days ago	Not required
MI-2026-0572	28 Aug 2026, 15:14	Web portal	HCP	DE	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Standard	Fatima Al-Sayed	Closed	Breached	16 days ago	Not required
MI-2026-0118	28 Aug 2026, 07:40	Web portal	HCP	GB	Lumeva	Use in pregnancy	Safety	Routine	Standard	Luis Ortega	Closed	Within SLA	13 days ago	Not required
MI-2026-0150	28 Aug 2026, 07:00	Web portal	HCP	ES	Lumeva	Use in pregnancy	Safety	Routine	Standard	Luis Ortega	Closed	Within SLA	13 days ago	Not required
MI-2026-0294	27 Aug 2026, 17:03	Email	HCP	DE	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Breached	14 days ago	Passed
MI-2026-0441	27 Aug 2026, 16:10	Congress booth	Patient	US	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Rachel Adeyemi	Sent	Within SLA	14 days ago	Not required
MI-2026-0396	27 Aug 2026, 15:30	Web portal	HCP	US	Vantrexa	Dose delay for grade 2 irAE	Dosing	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	14 days ago	Not required
MI-2026-0370	26 Aug 2026, 16:00	Phone	Patient	ES	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Luis Ortega	Closed	Within SLA	15 days ago	Passed
MI-2026-0256	26 Aug 2026, 11:25	Congress booth	Payer	GB	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	15 days ago	Not required
MI-2026-0501	25 Aug 2026, 16:12	Email	HCP	US	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Fatima Al-Sayed	Closed	Breached	19 days ago	Passed
MI-2026-0762	25 Aug 2026, 07:53	Web portal	Payer	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	16 days ago	Passed
MI-2026-0574	25 Aug 2026, 07:05	Web portal	Internal	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Sent	Within SLA	16 days ago	Passed
MI-2026-0696	24 Aug 2026, 16:09	Email	Pharmacist	US	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	17 days ago	Not required
MI-2026-0593	24 Aug 2026, 15:07	Web portal	Internal	GB	Vantrexa	Storage after dilution	Storage	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	17 days ago	Not required
MI-2026-0326	24 Aug 2026, 10:25	Email	HCP	FR	Vantrexa	Dose delay for grade 2 irAE	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	17 days ago	Not required
MI-2026-0465	24 Aug 2026, 09:05	Congress booth	HCP	DE	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	17 days ago	Not required
MI-2026-0559	24 Aug 2026, 08:54	Phone	HCP	JP	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	17 days ago	Not required
MI-2026-0682	22 Aug 2026, 18:04	MSL	HCP	US	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Rachel Adeyemi	Sent	Within SLA	19 days ago	Not required
MI-2026-0550	22 Aug 2026, 15:19	Email	HCP	GB	Nephrada	Mechanism versus budesonide formulations	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	19 days ago	Not required
MI-2026-0816	22 Aug 2026, 14:39	Email	Payer	ES	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	19 days ago	Not required
MI-2026-0199	22 Aug 2026, 13:55	Email	Patient	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Sent	Within SLA	19 days ago	Passed
MI-2026-0030	21 Aug 2026, 09:52	Email	Pharmacist	AU	Lumeva	Use in pregnancy	Safety	Routine	Standard	Luis Ortega	Closed	Within SLA	20 days ago	Not required
MI-2026-0070	21 Aug 2026, 09:13	Email	Payer	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	20 days ago	Passed
MI-2026-0663	20 Aug 2026, 18:04	Congress booth	Internal	DE	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Rachel Adeyemi	Closed	Breached	24 days ago	Passed
MI-2026-0149	20 Aug 2026, 14:09	Email	HCP	JP	Vantrexa	Use with untreated brain metastases	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	21 days ago	Passed
MI-2026-0661	20 Aug 2026, 12:52	Congress booth	Payer	US	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	21 days ago	Not required
MI-2026-0835	20 Aug 2026, 11:56	Web portal	HCP	JP	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	21 days ago	Not required
MI-2026-0240	20 Aug 2026, 10:48	Email	HCP	GB	Nephrada	Vaccination guidance	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	21 days ago	Not required
MI-2026-0832	20 Aug 2026, 08:37	MSL	HCP	DE	Vantrexa	Dose delay for grade 2 irAE	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	21 days ago	Not required
MI-2026-0625	19 Aug 2026, 14:55	Email	Payer	US	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	22 days ago	Not required
MI-2026-0335	19 Aug 2026, 14:00	Email	Internal	GB	Nephrada	Mechanism versus budesonide formulations	Efficacy	Urgent	Standard	Fatima Al-Sayed	Closed	Within SLA	25 days ago	Not required
MI-2026-0692	19 Aug 2026, 07:56	MSL	HCP	AU	Lumeva	Dosing in hepatic impairment	Dosing	Urgent	Standard	Luis Ortega	Closed	Breached	25 days ago	Not required
MI-2026-0018	18 Aug 2026, 16:05	Congress booth	HCP	CA	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Fatima Al-Sayed	Sent	Within SLA	23 days ago	Not required
MI-2026-0494	18 Aug 2026, 12:38	Web portal	Patient	BR	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Routine	Custom	Luis Ortega	Closed	Within SLA	23 days ago	Passed
MI-2026-0447	17 Aug 2026, 12:55	Congress booth	Payer	US	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	24 days ago	Passed
MI-2026-0367	17 Aug 2026, 07:37	Phone	Internal	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Breached	24 days ago	Passed
MI-2026-0227	16 Aug 2026, 18:18	Web portal	Payer	GB	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	25 days ago	Not required
MI-2026-0241	16 Aug 2026, 16:10	Web portal	Internal	AU	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	25 days ago	Not required
MI-2026-0109	15 Aug 2026, 17:23	Email	HCP	JP	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	26 days ago	Not required
MI-2026-0349	15 Aug 2026, 10:02	Email	HCP	US	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	26 days ago	Not required
MI-2026-0623	14 Aug 2026, 07:00	Email	HCP	US	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Archived	Within SLA	27 days ago	Not required
MI-2026-0777	13 Aug 2026, 09:37	Email	Payer	US	Vantrexa	Sequencing after progression	Efficacy	Urgent	Custom	Rachel Adeyemi	Closed	Breached	31 days ago	Passed
MI-2026-0532	13 Aug 2026, 08:25	MSL	HCP	DE	Nephrada	Vaccination guidance	Safety	Routine	Standard	Dr. Anna Becker	Archived	Within SLA	28 days ago	Not required
MI-2026-0193	12 Aug 2026, 18:45	Web portal	HCP	DE	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Standard	Dr. Anna Becker	Archived	Within SLA	29 days ago	Not required
MI-2026-0168	12 Aug 2026, 12:41	Web portal	HCP	DE	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Routine	Custom	Fatima Al-Sayed	Closed	Breached	29 days ago	Passed
MI-2026-0372	12 Aug 2026, 07:45	MSL	Patient	AU	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	29 days ago	Not required
MI-2026-0061	12 Aug 2026, 07:35	MSL	HCP	CA	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	29 days ago	Not required
MI-2026-0534	11 Aug 2026, 17:31	Phone	Patient	AU	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	30 days ago	Not required
MI-2026-0782	11 Aug 2026, 16:40	Phone	Patient	GB	Nephrada	Vaccination guidance	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	30 days ago	Not required
MI-2026-0609	11 Aug 2026, 09:50	Email	Internal	US	Vantrexa	Dose delay for grade 2 irAE	Dosing	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	30 days ago	Not required
MI-2026-0827	11 Aug 2026, 08:40	Congress booth	Pharmacist	GB	Nephrada	Mechanism versus budesonide formulations	Efficacy	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	30 days ago	Not required
MI-2026-0114	11 Aug 2026, 08:35	Web portal	Pharmacist	DE	Nephrada	Vaccination guidance	Safety	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	30 days ago	Not required
MI-2026-0719	11 Aug 2026, 08:12	Email	Patient	CA	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	30 days ago	Not required
MI-2026-0356	10 Aug 2026, 18:25	Phone	HCP	GB	Nephrada	Use in FSGS	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	31 days ago	Passed
MI-2026-0173	10 Aug 2026, 16:54	Web portal	Internal	US	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Rachel Adeyemi	Closed	Breached	34 days ago	Passed
MI-2026-0829	10 Aug 2026, 15:44	Congress booth	HCP	AU	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	31 days ago	Passed
MI-2026-0251	10 Aug 2026, 12:43	Web portal	Patient	DE	Nephrada	Use in FSGS	Off-label	Routine	Custom	Fatima Al-Sayed	Archived	Within SLA	31 days ago	Passed
MI-2026-0004	10 Aug 2026, 11:34	MSL	HCP	IT	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Luis Ortega	Archived	Within SLA	31 days ago	Not required
MI-2026-0261	10 Aug 2026, 11:27	Congress booth	Payer	GB	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	31 days ago	Not required
MI-2026-0653	10 Aug 2026, 10:06	Web portal	Internal	GB	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Standard	Fatima Al-Sayed	Closed	Within SLA	34 days ago	Not required
MI-2026-0639	09 Aug 2026, 17:01	Email	HCP	FR	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Rachel Adeyemi	Closed	Within SLA	35 days ago	Passed
MI-2026-0319	09 Aug 2026, 15:14	Email	Internal	JP	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Fatima Al-Sayed	Closed	Breached	32 days ago	Passed
MI-2026-0369	09 Aug 2026, 07:38	Email	Payer	DE	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	32 days ago	Not required
MI-2026-0756	08 Aug 2026, 18:31	Web portal	HCP	GB	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Rachel Adeyemi	Closed	Breached	36 days ago	Passed
MI-2026-0268	08 Aug 2026, 15:57	Email	HCP	CA	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Luis Ortega	Closed	Breached	33 days ago	Passed
MI-2026-0407	08 Aug 2026, 09:51	Phone	HCP	GB	Nephrada	Mechanism versus budesonide formulations	Efficacy	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	33 days ago	Not required
MI-2026-0703	08 Aug 2026, 08:47	Web portal	HCP	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	33 days ago	Passed
MI-2026-0262	08 Aug 2026, 07:00	Web portal	Patient	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	33 days ago	Passed
MI-2026-0518	07 Aug 2026, 15:19	Email	Patient	US	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	34 days ago	Passed
MI-2026-0453	07 Aug 2026, 07:59	Web portal	HCP	AU	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Luis Ortega	Closed	Within SLA	34 days ago	Findings
MI-2026-0385	07 Aug 2026, 07:28	MSL	Pharmacist	GB	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Fatima Al-Sayed	Closed	Breached	34 days ago	Passed
MI-2026-0522	06 Aug 2026, 16:48	Email	Pharmacist	JP	Vantrexa	Dose delay for grade 2 irAE	Dosing	Urgent	Standard	Fatima Al-Sayed	Closed	Within SLA	38 days ago	Not required
MI-2026-0221	05 Aug 2026, 13:06	Phone	Pharmacist	GB	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Urgent	Custom	Luis Ortega	Archived	Breached	39 days ago	Passed
MI-2026-0129	04 Aug 2026, 17:12	Phone	HCP	FR	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	37 days ago	Not required
MI-2026-0148	04 Aug 2026, 15:13	Web portal	Patient	US	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Archived	Within SLA	37 days ago	Passed
MI-2026-0727	04 Aug 2026, 07:54	Email	Internal	FR	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Rachel Adeyemi	Closed	Breached	40 days ago	Passed
MI-2026-0476	04 Aug 2026, 07:14	Phone	HCP	DE	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	37 days ago	Not required
MI-2026-0247	03 Aug 2026, 11:22	Congress booth	HCP	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	38 days ago	Findings
MI-2026-0552	03 Aug 2026, 10:35	Phone	Pharmacist	BR	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Breached	38 days ago	Passed
MI-2026-0005	03 Aug 2026, 10:21	Congress booth	Patient	CA	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	38 days ago	Not required
MI-2026-0276	02 Aug 2026, 18:16	MSL	Patient	ES	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	39 days ago	Not required
MI-2026-0201	02 Aug 2026, 16:49	MSL	Payer	US	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Breached	39 days ago	Findings
MI-2026-0047	02 Aug 2026, 07:18	Web portal	HCP	DE	Nephrada	Expanded access programme eligibility	Access	Urgent	Standard	Fatima Al-Sayed	Archived	Within SLA	42 days ago	Not required
MI-2026-0283	01 Aug 2026, 18:57	Email	Pharmacist	GB	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Closed	Breached	40 days ago	Passed
MI-2026-0556	01 Aug 2026, 13:38	Congress booth	Patient	JP	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	40 days ago	Passed
MI-2026-0817	31 Jul 2026, 18:38	Congress booth	HCP	FR	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	41 days ago	Not required
MI-2026-0387	31 Jul 2026, 18:08	MSL	Patient	US	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	41 days ago	Not required
MI-2026-0801	30 Jul 2026, 11:41	Email	Patient	DE	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	42 days ago	Not required
MI-2026-0778	30 Jul 2026, 11:36	Phone	HCP	IT	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	42 days ago	Not required
MI-2026-0834	29 Jul 2026, 12:28	Email	HCP	DE	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	43 days ago	Not required
MI-2026-0706	29 Jul 2026, 12:12	MSL	Patient	JP	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Luis Ortega	Archived	Within SLA	43 days ago	Not required
MI-2026-0231	28 Jul 2026, 17:01	Web portal	Pharmacist	FR	Vantrexa	Sequencing after progression	Efficacy	Critical	Custom	Fatima Al-Sayed	Closed	Breached	48 days ago	Passed
MI-2026-0606	28 Jul 2026, 16:45	Phone	HCP	CA	Lumeva	Co-administration with CYP3A4 inhibitors	Drug interaction	Routine	Standard	Luis Ortega	Closed	Within SLA	44 days ago	Not required
MI-2026-0277	28 Jul 2026, 15:38	Web portal	Payer	GB	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	44 days ago	Passed
MI-2026-0831	28 Jul 2026, 14:54	Phone	HCP	BR	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	44 days ago	Passed
MI-2026-0806	27 Jul 2026, 18:42	Email	Patient	BR	Lumeva	Missed-dose guidance	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	45 days ago	Not required
MI-2026-0200	27 Jul 2026, 08:54	Congress booth	Internal	IT	Lumeva	Washout when switching from anti-CGRP mAb	Drug interaction	Routine	Custom	Fatima Al-Sayed	Archived	Within SLA	45 days ago	Passed
MI-2026-0622	26 Jul 2026, 18:45	MSL	Patient	ES	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Luis Ortega	Archived	Breached	46 days ago	Passed
MI-2026-0152	26 Jul 2026, 18:05	MSL	Payer	US	Nephrada	Vaccination guidance	Safety	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	46 days ago	Not required
MI-2026-0432	26 Jul 2026, 16:00	Email	Pharmacist	BR	Lumeva	Use in pregnancy	Safety	Urgent	Standard	Fatima Al-Sayed	Closed	Within SLA	49 days ago	Not required
MI-2026-0531	26 Jul 2026, 11:08	Congress booth	HCP	US	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	46 days ago	Not required
MI-2026-0324	26 Jul 2026, 09:12	Email	HCP	DE	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	46 days ago	Not required
MI-2026-0299	25 Jul 2026, 17:06	Congress booth	HCP	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Archived	Breached	47 days ago	Passed
MI-2026-0322	25 Jul 2026, 16:54	Web portal	HCP	GB	Nephrada	Use in FSGS	Off-label	Routine	Custom	Dr. Anna Becker	Closed	Breached	47 days ago	Passed
MI-2026-0505	25 Jul 2026, 12:10	Phone	Payer	AU	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Luis Ortega	Closed	Breached	47 days ago	Passed
MI-2026-0043	25 Jul 2026, 10:25	Web portal	HCP	DE	Vantrexa	Reimbursement status by country	Access	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	47 days ago	Not required
MI-2026-0194	25 Jul 2026, 07:04	Email	Pharmacist	JP	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	47 days ago	Not required
MI-2026-0330	24 Jul 2026, 18:43	Email	HCP	JP	Vantrexa	Storage after dilution	Storage	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	48 days ago	Not required
MI-2026-0590	24 Jul 2026, 14:03	Email	HCP	DE	Vantrexa	Sequencing after progression	Efficacy	Routine	Custom	Fatima Al-Sayed	Archived	Within SLA	48 days ago	Passed
MI-2026-0564	24 Jul 2026, 07:08	MSL	HCP	US	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Custom	Fatima Al-Sayed	Closed	Breached	51 days ago	Passed
MI-2026-0253	23 Jul 2026, 17:26	Web portal	Payer	DE	Aurelin	Phase IIb results availability	Efficacy	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	49 days ago	Not required
MI-2026-0776	23 Jul 2026, 15:47	Email	HCP	US	Vantrexa	PD-L1 cut-off and assay compatibility	Administration	Routine	Standard	Rachel Adeyemi	Closed	Within SLA	49 days ago	Not required
MI-2026-0459	23 Jul 2026, 15:15	MSL	Payer	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Within SLA	49 days ago	Passed
MI-2026-0573	23 Jul 2026, 12:57	Phone	HCP	US	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	49 days ago	Not required
MI-2026-0179	22 Jul 2026, 16:29	Web portal	Pharmacist	JP	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Custom	Fatima Al-Sayed	Closed	Breached	50 days ago	Passed
MI-2026-0838	22 Jul 2026, 13:02	Phone	Payer	US	Nephrada	Vaccination guidance	Safety	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	50 days ago	Not required
MI-2026-0833	22 Jul 2026, 10:23	Congress booth	Internal	GB	Lumeva	Persistence data at 18 months	Efficacy	Routine	Custom	Fatima Al-Sayed	Closed	Breached	50 days ago	Passed
MI-2026-0645	22 Jul 2026, 08:25	Phone	Payer	JP	Vantrexa	Infusion time and line compatibility	Administration	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	50 days ago	Not required
MI-2026-0605	21 Jul 2026, 17:10	MSL	HCP	GB	Lumeva	Use in medication-overuse headache	Off-label	Routine	Custom	Fatima Al-Sayed	Closed	Breached	51 days ago	Findings
MI-2026-0536	21 Jul 2026, 16:52	Congress booth	HCP	DE	Nephrada	Expanded access programme eligibility	Access	Routine	Standard	Dr. Anna Becker	Closed	Within SLA	51 days ago	Not required
MI-2026-0800	21 Jul 2026, 16:07	Email	HCP	DE	Lumeva	Use in pregnancy	Safety	Urgent	Standard	Luis Ortega	Closed	Within SLA	54 days ago	Not required
MI-2026-0652	21 Jul 2026, 15:02	Email	Patient	ES	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	51 days ago	Not required
MI-2026-0033	21 Jul 2026, 14:39	MSL	Patient	DE	Aurelin	Compassionate use	Access	Routine	Custom	Fatima Al-Sayed	Closed	Breached	51 days ago	Passed
MI-2026-0246	21 Jul 2026, 09:59	Web portal	HCP	AU	Lumeva	Use in pregnancy	Safety	Routine	Standard	Fatima Al-Sayed	Closed	Within SLA	51 days ago	Not required
MI-2026-0746	21 Jul 2026, 08:50	Web portal	Pharmacist	JP	Lumeva	Dosing in hepatic impairment	Dosing	Routine	Standard	Luis Ortega	Closed	Within SLA	51 days ago	Not required

Showing 200 of 840 — refine filters to narrow the list. Open inquiries are listed first.

Topic	Product	Inquiries	Last 60 d vs prior 60 d	Standard response	Median response
Premedication after grade 1 infusion reaction	Vantrexa	57	16 (+6)	None	116 h	Create insight signal
Compassionate use	Aurelin	50	16 (+4)	None	110 h	Create insight signal
Missed-dose guidance	Lumeva	44	10 (-6)	None	35 h	Create insight signal
Dose delay for grade 2 irAE	Vantrexa	43	9 (-5)	Exists	33 h	Create insight signal
Sequencing after progression	Vantrexa	42	13 (+5)	None	115 h	Create insight signal
Storage after dilution	Vantrexa	41	6 (-9)	None	36 h	Create insight signal
Phase IIb results availability	Aurelin	41	9 (-1)	None	28 h	Create insight signal
Use in pregnancy	Lumeva	41	8 (-4)	Exists	37 h	Create insight signal
Reimbursement status by country	Vantrexa	40	8 (0)	None	24 h	Create insight signal
Infusion time and line compatibility	Vantrexa	40	9 (-2)	Exists	33 h	Create insight signal
Use with untreated brain metastases	Vantrexa	40	2 (-10)	None	101 h	Create insight signal
Vaccination guidance	Nephrada	39	10 (-1)	Exists	24 h	Create insight signal
PD-L1 cut-off and assay compatibility	Vantrexa	38	10 (-4)	Exists	36 h	Create insight signal
Washout when switching from anti-CGRP mAb	Lumeva	37	8 (+2)	None	114 h	Create insight signal
Dosing in hepatic impairment	Lumeva	35	11 (+4)	Exists	33 h	Create insight signal
Expanded access programme eligibility	Nephrada	34	9 (+3)	None	34 h	Create insight signal
Use in medication-overuse headache	Lumeva	33	10 (+4)	None	124 h	Create insight signal
Immunoglobulin monitoring frequency	Nephrada	32	11 (+6)	Exists	33 h	Create insight signal
Use in FSGS	Nephrada	32	11 (+5)	None	86 h	Create insight signal
Persistence data at 18 months	Lumeva	28	7 (+2)	None	85 h	Create insight signal
Co-administration with CYP3A4 inhibitors	Lumeva	27	12 (+10)	Exists	41 h	Create insight signal
Mechanism versus budesonide formulations	Nephrada	25	5 (0)	None	29 h	Create insight signal
Recurrent infections on extended treatment	Nephrada	1	1 (+1)	None	0 h	Create insight signal

Emerging topics (2)

Topics whose last-60-day count is at least twice the prior 60 days (minimum 3 inquiries).

Immunoglobulin monitoring frequency · Nephrada5 → 11
Co-administration with CYP3A4 inhibitors · Lumeva2 → 12

By category

840inquiries

Safety170 (20%)
Efficacy136 (16%)
Access124 (15%)
Dosing122 (15%)
Off-label105 (13%)
Administration78 (9%)
Drug interaction64 (8%)
Storage41 (5%)

By channel

840inquiries

Email235 (28%)
Web portal213 (25%)
MSL139 (17%)
Phone135 (16%)
Congress booth118 (14%)

By requestor type

HCP 346 · Payer 134 · Internal 132 · Patient 122 · Pharmacist 106

Volume by country

United States 221 · Germany 205 · United Kingdom 135 · Japan 84 · France 59 · Canada 32 · Italy 30 · Spain 27 · Australia 24 · Brazil 23

Standard responses (9)

ID	Product	Title	Version	Approved	Uses YTD	Matching inquiries (approx.)
SR-VTX-001	Vantrexa	PD-L1 cut-off and assay compatibility	v3	28 Mar 2026	61	38
SR-VTX-004	Vantrexa	Dose delay for grade 2 immune-related adverse events	v2	28 Mar 2026	44	43
SR-VTX-011	Vantrexa	Infusion time and line compatibility	v1	15 Apr 2026	37	40
SR-VTX-019	Vantrexa	Mechanistic differentiation from other TIGIT agents	v1	18 Jul 2026	22	0
SR-NPH-002	Nephrada	Immunoglobulin monitoring recommendations	v2	02 May 2026	28	32
SR-NPH-005	Nephrada	Vaccination guidance	v1	02 May 2026	17	39
SR-LMV-003	Lumeva	Dosing in hepatic impairment	v4	11 Jun 2026	58	35
SR-LMV-007	Lumeva	Co-administration with CYP3A4 inhibitors	v3	11 Jun 2026	49	27
SR-LMV-009	Lumeva	Use in pregnancy and lactation	v2	20 Feb 2026	31	41

Matching inquiries are matched on topic keywords within the same product and are approximate. Approved content is managed in Veeva Vault (INT-02).

Custom-response rate per product

Share of inquiries answered with a custom (non-standard) response

Vantrexa139 of 341
41%
Nephrada33 of 163
20%
Lumeva98 of 245
40%
Aurelin50 of 91
55%

Standard-response gaps (8)

Custom-response topics with ≥ 5 inquiries and no approved standard response

Topic	Product	Inquiries	Median response
Premedication after grade 1 infusion reaction	Vantrexa	57	116 h	No standard response
Compassionate use	Aurelin	50	110 h	No standard response
Sequencing after progression	Vantrexa	42	115 h	No standard response
Use with untreated brain metastases	Vantrexa	40	101 h	No standard response
Washout when switching from anti-CGRP mAb	Lumeva	37	114 h	No standard response
Use in medication-overuse headache	Lumeva	33	124 h	No standard response
Use in FSGS	Nephrada	32	86 h	No standard response
Persistence data at 18 months	Lumeva	28	85 h	No standard response

Potential adverse events (PRD §27.7)

Safety-related inquiries are captured minimally in this hub, access is restricted to the Medical Information and Safety roles, and each case is routed to pharmacovigilance per the customer SOP. Content of safety-flagged inquiries is never interpreted or summarised by AI.

Escalated or flagged

112

Currently open

Safety-flagged

Escalated and flagged inquiries

ID	Received	Product	Topic	Flags	Urgency	Status	SLA	Owner	Hours open
MI-2026-0812	14 Sept 2026, 08:12	Nephrada	Recurrent infections on extended treatment	EscalatedSafety	Critical	Escalated	Overdue	Fatima Al-Sayed	28 h (open)
MI-2026-0656	09 Sept 2026, 07:50	Nephrada	Use in FSGS	Escalated	Routine	Closed	Breached	Dr. Anna Becker	155 h
MI-2026-0763	08 Sept 2026, 11:32	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Closed	Within SLA	Rachel Adeyemi	44 h
MI-2026-0772	07 Sept 2026, 16:08	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Closed	Breached	Fatima Al-Sayed	59 h
MI-2026-0353	05 Sept 2026, 16:16	Vantrexa	Reimbursement status by country	Regulatory	Routine	Closed	Within SLA	Fatima Al-Sayed	12 h
MI-2026-0614	04 Sept 2026, 15:15	Nephrada	Vaccination guidance	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	40 h
MI-2026-0393	31 Aug 2026, 11:44	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	57 h
MI-2026-0145	30 Aug 2026, 18:13	Aurelin	Phase IIb results availability	Regulatory	Urgent	Sent	Breached	Fatima Al-Sayed	53 h
MI-2026-0637	30 Aug 2026, 10:02	Nephrada	Vaccination guidance	Safety	Urgent	Closed	Within SLA	Dr. Anna Becker	25 h
MI-2026-0572	28 Aug 2026, 15:14	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Closed	Breached	Fatima Al-Sayed	56 h
MI-2026-0118	28 Aug 2026, 07:40	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Luis Ortega	20 h
MI-2026-0150	28 Aug 2026, 07:00	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Luis Ortega	4 h
MI-2026-0030	21 Aug 2026, 09:52	Lumeva	Use in pregnancy	SafetyRegulatory	Routine	Closed	Within SLA	Luis Ortega	51 h
MI-2026-0663	20 Aug 2026, 18:04	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Closed	Breached	Rachel Adeyemi	97 h
MI-2026-0372	12 Aug 2026, 07:45	Lumeva	Missed-dose guidance	Regulatory	Routine	Closed	Within SLA	Luis Ortega	33 h
MI-2026-0653	10 Aug 2026, 10:06	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Closed	Within SLA	Fatima Al-Sayed	16 h
MI-2026-0319	09 Aug 2026, 15:14	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Closed	Breached	Fatima Al-Sayed	189 h
MI-2026-0756	08 Aug 2026, 18:31	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Urgent	Closed	Breached	Rachel Adeyemi	54 h
MI-2026-0385	07 Aug 2026, 07:28	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Closed	Breached	Fatima Al-Sayed	129 h
MI-2026-0221	05 Aug 2026, 13:06	Lumeva	Washout when switching from anti-CGRP mAb	Regulatory	Urgent	Archived	Breached	Luis Ortega	151 h
MI-2026-0552	03 Aug 2026, 10:35	Lumeva	Use in medication-overuse headache	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	143 h
MI-2026-0556	01 Aug 2026, 13:38	Vantrexa	Sequencing after progression	Regulatory	Routine	Closed	Within SLA	Fatima Al-Sayed	114 h
MI-2026-0801	30 Jul 2026, 11:41	Vantrexa	PD-L1 cut-off and assay compatibility	Regulatory	Routine	Closed	Within SLA	Rachel Adeyemi	54 h
MI-2026-0622	26 Jul 2026, 18:45	Lumeva	Use in medication-overuse headache	Escalated	Routine	Archived	Breached	Luis Ortega	124 h
MI-2026-0152	26 Jul 2026, 18:05	Nephrada	Vaccination guidance	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	14 h
MI-2026-0299	25 Jul 2026, 17:06	Aurelin	Compassionate use	Escalated	Routine	Archived	Breached	Fatima Al-Sayed	142 h
MI-2026-0564	24 Jul 2026, 07:08	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Urgent	Closed	Breached	Fatima Al-Sayed	101 h
MI-2026-0800	21 Jul 2026, 16:07	Lumeva	Use in pregnancy	Safety	Urgent	Closed	Within SLA	Luis Ortega	23 h
MI-2026-0311	20 Jul 2026, 16:03	Vantrexa	Use with untreated brain metastases	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	149 h
MI-2026-0471	18 Jul 2026, 09:33	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Closed	Breached	Fatima Al-Sayed	113 h
MI-2026-0599	17 Jul 2026, 16:43	Vantrexa	Dose delay for grade 2 irAE	Regulatory	Routine	Closed	Within SLA	Rachel Adeyemi	57 h
MI-2026-0458	17 Jul 2026, 11:18	Aurelin	Compassionate use	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	183 h
MI-2026-0226	16 Jul 2026, 16:48	Lumeva	Persistence data at 18 months	Escalated	Routine	Closed	Breached	Luis Ortega	121 h
MI-2026-0024	16 Jul 2026, 11:26	Aurelin	Compassionate use	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	145 h
MI-2026-0041	11 Jul 2026, 18:02	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	13 h
MI-2026-0450	08 Jul 2026, 09:54	Lumeva	Washout when switching from anti-CGRP mAb	Escalated	Routine	Archived	Within SLA	Fatima Al-Sayed	117 h
MI-2026-0596	29 Jun 2026, 12:43	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Closed	Within SLA	Rachel Adeyemi	33 h
MI-2026-0769	24 Jun 2026, 08:38	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Urgent	Closed	Within SLA	Fatima Al-Sayed	30 h
MI-2026-0313	21 Jun 2026, 12:03	Aurelin	Compassionate use	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	67 h
MI-2026-0728	21 Jun 2026, 08:15	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	54 h
MI-2026-0545	18 Jun 2026, 17:29	Lumeva	Use in pregnancy	Safety	Urgent	Archived	Within SLA	Fatima Al-Sayed	21 h
MI-2026-0237	11 Jun 2026, 16:19	Nephrada	Use in FSGS	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	81 h
MI-2026-0717	11 Jun 2026, 11:31	Lumeva	Use in medication-overuse headache	Escalated	Urgent	Closed	Breached	Luis Ortega	163 h
MI-2026-0343	10 Jun 2026, 13:08	Vantrexa	Sequencing after progression	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	160 h
MI-2026-0430	07 Jun 2026, 11:32	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Routine	Closed	Breached	Rachel Adeyemi	162 h
MI-2026-0730	05 Jun 2026, 13:21	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Routine	Closed	Breached	Rachel Adeyemi	147 h
MI-2026-0391	05 Jun 2026, 11:38	Lumeva	Washout when switching from anti-CGRP mAb	Escalated	Routine	Closed	Within SLA	Luis Ortega	71 h
MI-2026-0797	28 May 2026, 16:12	Aurelin	Compassionate use	Escalated	Critical	Closed	Breached	Fatima Al-Sayed	49 h
MI-2026-0460	25 May 2026, 11:28	Nephrada	Use in FSGS	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	66 h
MI-2026-0399	25 May 2026, 10:51	Lumeva	Use in medication-overuse headache	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	58 h
MI-2026-0617	24 May 2026, 10:25	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Urgent	Closed	Breached	Fatima Al-Sayed	163 h
MI-2026-0375	23 May 2026, 16:15	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Critical	Closed	Breached	Fatima Al-Sayed	103 h
MI-2026-0063	22 May 2026, 08:43	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Archived	Breached	Rachel Adeyemi	108 h
MI-2026-0058	21 May 2026, 17:03	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	54 h
MI-2026-0610	18 May 2026, 14:10	Nephrada	Use in FSGS	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	83 h
MI-2026-0019	17 May 2026, 15:00	Lumeva	Washout when switching from anti-CGRP mAb	Regulatory	Routine	Closed	Breached	Fatima Al-Sayed	123 h
MI-2026-0174	15 May 2026, 13:11	Lumeva	Use in pregnancy	Safety	Routine	Archived	Within SLA	Luis Ortega	41 h
MI-2026-0280	10 May 2026, 07:00	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Urgent	Archived	Breached	Fatima Al-Sayed	150 h
MI-2026-0683	06 May 2026, 13:10	Aurelin	Compassionate use	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	40 h
MI-2026-0410	05 May 2026, 16:28	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Urgent	Closed	Breached	Fatima Al-Sayed	162 h
MI-2026-0690	27 Apr 2026, 17:56	Vantrexa	Dose delay for grade 2 irAE	Regulatory	Routine	Closed	Within SLA	Fatima Al-Sayed	37 h
MI-2026-0615	26 Apr 2026, 16:12	Vantrexa	Premedication after grade 1 infusion reaction	EscalatedSafety	Routine	Closed	Within SLA	Rachel Adeyemi	25 h
MI-2026-0449	25 Apr 2026, 15:06	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Routine	Closed	Within SLA	Rachel Adeyemi	89 h
MI-2026-0310	25 Apr 2026, 12:05	Nephrada	Vaccination guidance	Safety	Routine	Closed	Within SLA	Dr. Anna Becker	60 h
MI-2026-0213	23 Apr 2026, 09:26	Lumeva	Washout when switching from anti-CGRP mAb	Regulatory	Routine	Closed	Breached	Fatima Al-Sayed	127 h
MI-2026-0589	21 Apr 2026, 16:59	Vantrexa	Reimbursement status by country	Regulatory	Routine	Closed	Within SLA	Fatima Al-Sayed	49 h
MI-2026-0770	21 Apr 2026, 14:52	Lumeva	Use in medication-overuse headache	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	71 h
MI-2026-0566	15 Apr 2026, 16:48	Vantrexa	Use with untreated brain metastases	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	81 h
MI-2026-0013	15 Apr 2026, 14:21	Vantrexa	Dose delay for grade 2 irAE	Regulatory	Routine	Closed	Within SLA	Fatima Al-Sayed	16 h
MI-2026-0378	14 Apr 2026, 07:38	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Luis Ortega	6 h
MI-2026-0824	13 Apr 2026, 15:03	Lumeva	Washout when switching from anti-CGRP mAb	Escalated	Routine	Closed	Breached	Luis Ortega	182 h
MI-2026-0342	11 Apr 2026, 07:53	Vantrexa	Use with untreated brain metastases	Escalated	Routine	Closed	Within SLA	Rachel Adeyemi	71 h
MI-2026-0519	10 Apr 2026, 11:25	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	52 h
MI-2026-0587	10 Apr 2026, 09:48	Aurelin	Compassionate use	Escalated	Critical	Closed	Breached	Fatima Al-Sayed	111 h
MI-2026-0079	08 Apr 2026, 14:53	Lumeva	Use in medication-overuse headache	Escalated	Routine	Closed	Within SLA	Luis Ortega	54 h
MI-2026-0583	08 Apr 2026, 10:46	Vantrexa	PD-L1 cut-off and assay compatibility	Regulatory	Routine	Closed	Within SLA	Rachel Adeyemi	55 h
MI-2026-0139	06 Apr 2026, 08:10	Nephrada	Vaccination guidance	Safety	Routine	Closed	Within SLA	Dr. Anna Becker	41 h
MI-2026-0051	06 Apr 2026, 07:20	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Urgent	Closed	Breached	Rachel Adeyemi	141 h
MI-2026-0373	01 Apr 2026, 17:03	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Closed	Within SLA	Dr. Anna Becker	18 h
MI-2026-0551	31 Mar 2026, 09:19	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	37 h
MI-2026-0198	29 Mar 2026, 15:39	Aurelin	Compassionate use	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	141 h
MI-2026-0287	25 Mar 2026, 13:55	Nephrada	Vaccination guidance	Safety	Urgent	Closed	Within SLA	Fatima Al-Sayed	10 h
MI-2026-0105	24 Mar 2026, 09:55	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	9 h
MI-2026-0216	24 Mar 2026, 07:18	Vantrexa	Use with untreated brain metastases	Regulatory	Routine	Closed	Within SLA	Fatima Al-Sayed	51 h
MI-2026-0085	23 Mar 2026, 17:28	Vantrexa	Premedication after grade 1 infusion reaction	EscalatedSafety	Routine	Closed	Within SLA	Rachel Adeyemi	99 h
MI-2026-0401	18 Mar 2026, 07:25	Nephrada	Immunoglobulin monitoring frequency	Safety	Urgent	Closed	Within SLA	Dr. Anna Becker	9 h
MI-2026-0541	15 Mar 2026, 10:46	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Closed	Breached	Fatima Al-Sayed	172 h
MI-2026-0740	05 Mar 2026, 07:07	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	181 h
MI-2026-0192	02 Mar 2026, 15:04	Lumeva	Use in medication-overuse headache	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	31 h
MI-2026-0435	02 Mar 2026, 10:21	Lumeva	Washout when switching from anti-CGRP mAb	Regulatory	Routine	Closed	Breached	Fatima Al-Sayed	122 h
MI-2026-0123	01 Mar 2026, 13:35	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	56 h
MI-2026-0305	27 Feb 2026, 12:37	Vantrexa	Use with untreated brain metastases	Escalated	Routine	Closed	Breached	Rachel Adeyemi	162 h
MI-2026-0094	26 Feb 2026, 18:14	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Closed	Breached	Fatima Al-Sayed	156 h
MI-2026-0155	15 Feb 2026, 18:06	Vantrexa	Premedication after grade 1 infusion reaction	Escalated	Routine	Closed	Breached	Rachel Adeyemi	189 h
MI-2026-0607	15 Feb 2026, 13:46	Nephrada	Vaccination guidance	Safety	Urgent	Closed	Breached	Fatima Al-Sayed	57 h
MI-2026-0309	13 Feb 2026, 16:59	Vantrexa	Sequencing after progression	Escalated	Urgent	Closed	Breached	Fatima Al-Sayed	108 h
MI-2026-0723	12 Feb 2026, 08:24	Vantrexa	Premedication after grade 1 infusion reaction	EscalatedSafety	Routine	Archived	Within SLA	Fatima Al-Sayed	70 h
MI-2026-0689	10 Feb 2026, 14:07	Nephrada	Vaccination guidance	Safety	Urgent	Closed	Within SLA	Fatima Al-Sayed	22 h
MI-2026-0704	07 Feb 2026, 11:42	Lumeva	Persistence data at 18 months	Escalated	Routine	Closed	Breached	Luis Ortega	134 h
MI-2026-0820	05 Feb 2026, 10:11	Vantrexa	Use with untreated brain metastases	Escalated	Routine	Closed	Breached	Rachel Adeyemi	142 h
MI-2026-0272	04 Feb 2026, 14:25	Aurelin	Compassionate use	Escalated	Routine	Closed	Within SLA	Fatima Al-Sayed	111 h
MI-2026-0488	02 Feb 2026, 15:03	Aurelin	Compassionate use	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	167 h
MI-2026-0720	29 Jan 2026, 18:19	Vantrexa	Premedication after grade 1 infusion reaction	Safety	Routine	Closed	Breached	Fatima Al-Sayed	156 h
MI-2026-0228	27 Jan 2026, 16:23	Lumeva	Persistence data at 18 months	Escalated	Routine	Closed	Breached	Luis Ortega	128 h
MI-2026-0292	22 Jan 2026, 07:27	Lumeva	Use in medication-overuse headache	Escalated	Urgent	Closed	Breached	Luis Ortega	180 h
MI-2026-0217	17 Jan 2026, 07:27	Vantrexa	Premedication after grade 1 infusion reaction	EscalatedSafety	Routine	Archived	Within SLA	Fatima Al-Sayed	83 h
MI-2026-0215	15 Jan 2026, 11:02	Nephrada	Immunoglobulin monitoring frequency	Safety	Routine	Closed	Within SLA	Dr. Anna Becker	53 h
MI-2026-0214	14 Jan 2026, 18:03	Lumeva	Use in pregnancy	Safety	Routine	Closed	Within SLA	Fatima Al-Sayed	59 h
MI-2026-0295	14 Jan 2026, 11:35	Lumeva	Use in pregnancy	Safety	Urgent	Archived	Within SLA	Fatima Al-Sayed	29 h
MI-2026-0651	13 Jan 2026, 15:17	Vantrexa	Premedication after grade 1 infusion reaction	SafetyRegulatory	Routine	Closed	Breached	Rachel Adeyemi	131 h
MI-2026-0337	12 Jan 2026, 16:51	Nephrada	Use in FSGS	Escalated	Routine	Closed	Breached	Dr. Anna Becker	122 h
MI-2026-0184	08 Jan 2026, 17:44	Lumeva	Washout when switching from anti-CGRP mAb	Escalated	Routine	Closed	Breached	Fatima Al-Sayed	177 h

112 inquiries · open first.

Handoff log — MI-2026-0812

Pharmacovigilance handoff for the critical safety-flagged inquiry (demo)

Open inquiry

14 Sept 2026, 08:12 UTC
Inquiry received via MSL
Recurrent infections on extended treatment · Nephrada · Germany
14 Sept 2026, 08:14 UTC
PV notified
Routed to Safety per SOP-PV-014; audit event AUD-001802.
14 Sept 2026, 13:05 UTC
Related insight INS-0058 routed to Safety
Potential adverse event handoff recorded (AUD-001760). Action ACT-0021 open with Safety.
15 Sept 2026, 08:12 UTC
24-hour SLA breached
Issue ISS-0003 opened. 4 h past due at 15 Sept 2026, 12:00 UTC.

Related insight: INS-0058

Medical Information

Monthly volume by product

SLA compliance per month

Inquiries (840)

Top topics (23)

Emerging topics (2)

By category

By channel

By requestor type

Volume by country

Standard responses (9)

Custom-response rate per product

Standard-response gaps (8)

Escalated and flagged inquiries

Handoff log — MI-2026-0812

Medical Information

Monthly volume by product

SLA compliance per month

Inquiries (840)

Top topics (23)

Emerging topics (2)

By category

By channel

By requestor type

Volume by country

Standard responses (9)

Custom-response rate per product

Standard-response gaps (8)

Escalated and flagged inquiries

Handoff log — MI-2026-0812